For which patients?
Since the results of the VISION study (registration study), Lu-177-PSMA therapy has become a proven treatment worldwide and has been registered by the FDA and EMA. However, Lutetium-PSMA therapy is not yet a standard treatment in the Netherlands and in some cases is not reimbursed by health insurance companies . .
In general, it is important for PSMA therapy that the metastases on a PSMA PET/CT show good uptake of PSMA. Only if there is a lot of PSMA in the metastases can it have a beneficial effect. In addition, several other organs, especially the bone marrow, kidneys, and liver, must function reasonably well for the treatment to be well tolerated.